H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) today and set a price target of $25. The company’s shares closed yesterday at $4.70, close to its 52-week low of $4.60.
“Valuation methodology, risks and uncertainties. 15% discount rate, a 70% probability of success for ORMD-0801, and peak annual sales of roughly $2.1B (on which we project double-digit percentage royalties), we derive a total rNPV of $150M. We add to this the value from Oramed’s pipeline, mainly ORMD-0901, to which we ascribe a total valuation of $210M, to derive a total firm value of $385M.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of 0.0% and a 35.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.
Oramed Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $15.
Based on Oramed Pharmaceuticals’ latest earnings release for the quarter ending May 31, the company reported a quarterly GAAP net loss of $4.35 million. In comparison, last year the company had a GAAP net loss of $2.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.